330 related articles for article (PubMed ID: 18544001)
1. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Hafner V; Czock D; Burhenne J; Riedel KD; Bommer J; Mikus G; Machleidt C; Weinreich T; Haefeli WE
Antimicrob Agents Chemother; 2010 Jun; 54(6):2596-602. PubMed ID: 20368400
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.
Luke DR; Wood ND; Tomaszewski KE; Damle B
Nephrol Dial Transplant; 2012 Mar; 27(3):1207-12. PubMed ID: 21868395
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intravenous voriconazole in patients with compromised renal function.
Lilly CM; Welch VL; Mayer T; Ranauro P; Meisner J; Luke DR
BMC Infect Dis; 2013 Jan; 13():14. PubMed ID: 23320795
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.
Oude Lashof AM; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Schlamm HT; Rex JH; Kullberg BJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):3133-7. PubMed ID: 22450974
[TBL] [Abstract][Full Text] [Related]
7. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).
Luke DR; Tomaszewski K; Damle B; Schlamm HT
J Pharm Sci; 2010 Aug; 99(8):3291-301. PubMed ID: 20213839
[TBL] [Abstract][Full Text] [Related]
8. Administration of voriconazole in patients with renal dysfunction.
Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA
Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
von Mach MA; Burhenne J; Weilemann LS
BMC Clin Pharmacol; 2006 Sep; 6():6. PubMed ID: 16981986
[TBL] [Abstract][Full Text] [Related]
13. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.
Purkins L; Wood N; Ghahramani P; Love ER; Eve MD; Fielding A
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):37-44. PubMed ID: 14616412
[TBL] [Abstract][Full Text] [Related]
16. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
Purkins L; Wood N; Ghahramani P; Kleinermans D; Layton G; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):30-6. PubMed ID: 14616411
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.
Purkins L; Wood N; Kleinermans D; Greenhalgh K; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):17-23. PubMed ID: 14616409
[TBL] [Abstract][Full Text] [Related]
19. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
